Moody National Bank Trust Division Lowers Stock Position in Boston Scientific Corporation $BSX

Moody National Bank Trust Division cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 7.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,486 shares of the medical equipment provider’s stock after selling 270 shares during the quarter. Moody National Bank Trust Division’s holdings in Boston Scientific were worth $374,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Sunbeam Capital Management LLC bought a new position in Boston Scientific in the fourth quarter valued at $26,000. 1248 Management LLC purchased a new stake in Boston Scientific in the first quarter worth approximately $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the 1st quarter valued at $27,000. Ameriflex Group Inc. purchased a new position in shares of Boston Scientific in the fourth quarter worth about $31,000. Finally, Fourth Dimension Wealth LLC purchased a new position in Boston Scientific in the 4th quarter worth approximately $36,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.4%

NYSE:BSX opened at $97.84 on Friday. The stock has a market cap of $144.97 billion, a price-to-earnings ratio of 58.24, a PEG ratio of 2.36 and a beta of 0.65. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average price is $104.40 and its 200-day moving average price is $102.09. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the firm posted $0.62 EPS. The firm’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BSX has been the topic of several recent analyst reports. Wells Fargo & Company raised their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Raymond James Financial lifted their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $118.04.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.